Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
US Market

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Income Statement

498 Followers

Structure Therapeutics, Inc. Sponsored ADR Income Statement

Last quarter (Q1 2024), Structure Therapeutics, Inc. Sponsored ADR's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, Structure Therapeutics, Inc. Sponsored ADR's net income was $-26.04M. See Structure Therapeutics, Inc. Sponsored ADR’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
--$ 0.00$ 0.00$ 0.00
Cost of Revenue
-----
Gross Profit
-----
Operating Expense
$ 115.14M$ 102.78M$ 52.56M$ 37.70M$ 15.91M
Operating Income
$ -115.14M$ -102.78M$ -52.56M$ -37.70M$ -15.91M
Net Non Operating Interest Income Expense
--$ 1.26M$ -122.00K$ 168.00K
Other Income Expense
$ 1.70M----
Pretax Income
$ -97.44M$ -89.38M$ -51.30M$ -37.82M$ -15.74M
Tax Provision
$ 240.00K$ 236.00K$ 17.00K$ 231.00K$ 138.00K
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -97.68M$ -89.62M$ -52.84M$ -43.77M$ -16.04M
Basic EPS
$ -0.78$ -0.81$ -1.38$ -1.75$ -1.59
Diluted EPS
$ -0.78$ -0.81$ -1.38$ -1.75$ -1.59
Basic Average Shares
$ 508.85M$ 110.20M$ 38.24M$ 25.05M$ 25.05M
Diluted Average Shares
$ 508.85M$ 110.20M$ 38.24M$ 25.48M$ 25.05M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 115.14M$ 102.78M$ 52.56M$ 37.70M$ 15.91M
Net Income From Continuing And Discontinued Operation
$ -97.68M$ -89.62M$ -51.32M$ -40.01M$ -15.88M
Normalized Income
$ -87.70M$ -70.61M$ -51.32M$ -40.01M$ -15.88M
Interest Expense
-----
EBIT
$ -103.45M$ -89.38M$ -52.56M$ -37.70M$ -15.91M
EBITDA
$ -103.00M$ -89.09M$ -52.28M$ -37.62M$ -15.91M
Currency in USD

Structure Therapeutics, Inc. Sponsored ADR Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis